Status:
UNKNOWN
Olmesartan on Ambulatory Blood Pressure Change
Lead Sponsor:
National Taiwan University Hospital
Conditions:
Hypertension
Eligibility:
All Genders
18-90 years
Brief Summary
We will conduct an open label, non-comparative, observational study to evaluate the efficacy, safety and tolerability of Olmesartan therapy in Taiwan patients with essential hypertension, and the prim...
Detailed Description
Vitamin D plays an important role for cardiac function and blood pressure regulation, and the serum 25(OH)D concentration change is an important indicator for Vitamin D nutritional status, and serum 1...
Eligibility Criteria
Inclusion
- Male or female, 18 years of age or over.
- naïve patients with Stage I\*\* or Stage II\*\* (JNC VII) essential hypertension or patients uncontrolled on current hypotensive drug therapy (in cuff BP\>140/90mm Hg)
- All selected patients must give their written informed consent before recording their personal data
Exclusion
- Subject with secondary form of hypertension
- Subject is being treated or with unstable condition for disease of myocardial infarction, clinically decompensated congestive heart failure, angina pectoris, sick sinus syndrome, second or third degree atrioventricular block
- Subject with history of hypertensive encephalopathy, grade 3 or 4 hypertensive retinopathy within 3 months before entering this trial
- Subjects with a cerebrovascular accident within 6 months before entering this trial
- Subject with auto-immune disease
- Subject with uncontrolled endocrine diseases, such as Hyperthyroidism, Hypothyroidism, Hypercorticism and Hypocorticism
- Subject with confirmed evidence of renal impairment (creatinine \> 1.5 x upper limit of normal)
- Subject with hyperkalemia with serum potassium \> 5.5 meq/L
- Subject with terminal stage of malignant disease
- Subject with substance abuse history
- Subject with gastrointestinal disease which can interfere the absorption of the oral medications
- Subject with any contraindication to the use of angiotensin II receptor blocker or calcium channel blocker
- Subject is pregnant or lactating
- Premenopausal subjects not taking reliable methods for contraceptives
- Subject with any other serious disease considered by the investigator not in the condition to enter the trial
- Subject is not able to comply to the protocol requirements
- Subject participated investigational drug trial within 3 months before entering this study
Key Trial Info
Start Date :
April 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00854763
Start Date
April 1 2009
Last Update
March 3 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital
Taipei, Taiwan, 100